EFFECTS OF THERAPEUTIC ANTICOAGULATION FOR SARS-COV-2 COAGULOPATHY ON
MARKERS OF INFLAMMATION AND MORTALITY
Lyndsey Turbow , Nancy Guirguis (1), Praveena Tathineni , Dana Mueller , Tyler Cooper , Daniel Thompson , Nicholas Goodmanson , John Weissert , Kouroush Ravvaz , Kenneth Dodd
(1)

(1)

(1)

(1)

(1)

(2)

(3)

(3)

(1,2,4)

(1) Department of Internal Medicine, Advocate Christ Medical Center; (2) Pulmonology & Critical Care Faculty, Advocate Christ Medical Center, (3) Advocate Aurora Reserach Institute, Milwaukee, WI (4) Department of
Emergency Medicine, Advocate Christ Medical Center

The Novel Virus and
Anticoagulation

Results
Of 145 subjects, 67 (46%) received therapeutic anticoagulation; 58 (87%) for
COVID-19 coagulopathy and 12 (18%) for thrombotic events. Initial median [IQR]

Thromboembolic events are a recognized and feared complication of the Novel

serum values were as follows: CRP 14 mg/dL (9-21), d-dimer 8.1 mg/L (4.3-18.6),

2019 SARS-CoV-2 virus responsible for the 2019 COVID pandemic 1. Emerging

ferritin 1,614 ng/mL (723-2526) and LDH 445 units/L (356-629). Five days after

data suggests that significant end organ damage occurs as a result of

initiation of anticoagulation all patients had a decrease in all measured serum

microthrombi formation within these organ systems 2. Serum markers, namely

values: CRP 6.8 (2.5-9), LDH 385 (297-472), D-Dimer 4.1 (2.3-7.9) and Ferritin 975

C Reactive Protein (CRP), D-Dimer, Ferritin and Lactate Dehydrogenase

(646-1483; P < 0.05 for all). At the time of follow-up, 23 (34%) patients had been

(LDH) are used a as surrogates to measure ths process. Practitioners have

discharged alive, 20 (30%) patients had expired, and 24 (36%) patients remained

been using therapeutic anticoagulation to treat and oftentimes prevent these

in-hospital. Mortality was directly associated with age (HR 9.05; 95%CI 1.71-46)

occurrences with little data regarding their effects on these serum

and post-anticoagulation d-dimer level (HR 9.78; 95%CI 1.81-52.9; P < 0.01 for

inflammatory markers. Furthermore, it was not well understood the effects

both), and inversely associated with obesity (HR 0.27, 95%CI 0.80-0.93; P < 0.05

that discreet patient variables would have on clinical outcomes of patients

for all).

receiving therapeutic anticoagulation.

Figure 1. Change in Serum Laboratory Values After Initiation of Therapeutic Anticoagulation

Discussion
This study is the first report the effects of therapeutic anticoagulation on proinflammatory serum markers. In this population, the results show a statistically
significant decrease in these markers which may suggest not only efficacy in
prevention/treatment of thrombotic disease, but also may speak to the antiinflammatory properties of UFH itself.
Older age and higher d-dimer levels were identified as risk factors for mortality in
this study. Specifically, we found that age greater than 65 years-old and a increased
d-dimer were associated with higher mortality rates.
The majority of this critically ill population was obese, consistent with prior data
showing obesity to be a strong risk factor for clinically severe COVID-19 infection3.
In contrast to prior studies, however, we found that BMI greater than 30
kg/m2 conferred a lower risk of death in patients on therapeutic anticoagulation. UFH
therapy in obese patients has unique attributes, including close monitoring of

The Formal Evaluation

weight-based dosing, that may help obese patients achieve target dosing range
more quickly. We also propose that therapeutic anticoagulation with UFH may also

In this single center, retrospective cohort study, we identified 145 COVID

uniquely benefit obese patients by addressing the higher rates of thrombotic

positive, adult patients admitted to the medical intensive care unit

disease and the inflammatory state associated with obesity. The therapeutic roles of

(ICU) between March 3, 2020, and April 12, 2020. Patients were initiated

heparin in obese COVID positive patients will require further exploration.

on parenteral therapeutic anticoagulation with unfractionated heparin (UFH) at
the discretion of the care provider. Informal indications for initiation of
anticoagulation, based on common practice, became D-Dimer greater than six

Conclusions

times the upper limit of normal (>6x ULN), a Sepsis Induced Coagulopathy
(SIC) score of greater than 4, or evidence of thrombotic disease. Demographic
and laboratory data was collected on each of the subjects upon ICU admission
and repeated on days one, three, five and seven of admission and at the

In this patient population, therapeutic anticoagulation was associated with a
Legend for Figure 1. This figure depicts the changes in d-dimer, c-reactive protein,
lactate dehydrogenase and ferritin from the time of admission and then at days 1, 3
and 5 after starting therapeutic anticoagulation.

test. Multivariate analyses for predicting death were calculated using Cox

may have a particularly important role in obese patients, as obesity was associated
with higher survival in patients placed on anticoagulation. This study provides

conclusion of the follow up period when patient outcomes were
also documented. Comparisons were made using two-sided Mann-Whitney U

decrease in inflammatory markers, suggesting efficacy of treatment. Anticoagulation

Figure 2. Kaplan-Meier Estimate of Mortality in Critically Ill Patients Undergoing Therapeutic
Anticoagulation for COVID-19 Coagulopathy

important data for larger, prospective trials.

proportional- hazards models. Survival analyses were conductedd using
Kaplan-Meier estimators for death, stratified by age, d-dimer, and BMI. Patients
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Figure 2 Legend. These Kaplan-Meier estimator curves depict the mortality of the
patient sample according to (left-to-right) age > 65 years-old, BMI > 30 kg/m2, and
final d-dimer* >4.69 mg/L. Definitions: BMI, Body mass index.
* Final D-dimer was defined as the last available serum d-dimer result measured
after initiating therapeutic anticoagulation. D-dimer values were stratified by the
median of the cohort (4.69 mg/L).
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